There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.
Eli Lilly and Company LLY dropped 6.6% in the Jan. 14 trading session after slashing its revenue guidance for the fourth quarter and fiscal 2024, citing lower-than-expected sales for its weight-loss ...
Medical experts proposed a radical overhaul of how obesity is diagnosed, moving away from relying on body mass alone and ...
The recommendation signals a long-awaited shift from a single imperfect metric toward a more personalised diagnosis ...
SAN FRANCISCO — When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which ...
The S&P 500 added 0.1% on Tuesday, Jan. 14, as tame wholesale inflation data provided a positive signal ahead of Wednesday's ...
Companies from Johnson & Johnson to Eli Lilly, Amazon and Nvidia are announcing health-related deals at the JPMorgan Health ...
Several large drugmakers will ask the Trump administration to pause Medicare drug-price negotiations, even as Biden-appointed ...
Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the ...
Kristin Sherman leads startup Kovina Therapeutics, which is still in the early stages of developing ways to stop human ...
Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things ...
Medicare drug plans can now cover Eli Lilly & Co.'s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that's expected to prove a big boost for the drug company.